drugset / Trial / NCT06447779

Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older

NCT06447779

Phase 3 Active not recruiting 25000 enrolled MAXVAX Biotechnology Limited Liability Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.

Timeline

Start
2024-07-13
Primary completion
2025-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Zoster Vaccine (CHO Cell) Vaccine 50 ug Intramuscular
Subject Recombinant Zoster Vaccine (CHO Cell) Vaccine 0.5 ml Intramuscular

Indications